

1
2
3 **Early population-based outcomes of infants born with congenital**
4 **diaphragmatic hernia**
5
6
7

8
9 **Long AM^{1,2}, Bunch KJ¹, Knight M¹, Kurinczuk JJ¹, Losty PD^{2,3} - On behalf of BAPS-CASS**
10
11

12
13 **Author Affiliations**
14

- 15 1. National Perinatal Epidemiology Unit, University of Oxford
16 2. Alder Hey Children's Hospital, Liverpool
17 3. Institute of Child Health, University of Liverpool
18
19
20

21
22 **Corresponding Author**
23

24 Professor Paul Losty MD FRCSI FRCS(Ed) FRCS(Eng) FRCS(Paed) FEBPS
25 Professor of Paediatric Surgery
26 Department of Women and Children's Health
27 Institute of Translational Medicine
28 University of Liverpool
29 Alder Hey Children's Hospital NHS Foundation Trust
30 East Prescott Rd
31 Liverpool L14 5AB, UK
32 Tel: 00-44-151 228 4811
33 Email : paul.Losty@liverpool.ac.uk
34
35

36 **Source of Funding**
37

38 Action Medical Research
39

40 **Category of submission**
41

42 Original article
43
44
45
46
47
48
49

50 Word Count 2518
51
52
53
54
55
56
57
58
59
60

Abstract

Purpose

This study aims to describe short-term outcomes of live born infants with congenital diaphragmatic hernia (CDH) and to identify prognostic factors associated with early mortality.

Design

A prospective population cohort study was undertaken between April 2009 and September 2010, collecting data on live-born infants with CDH from all 28 paediatric surgical centres in the UK and Ireland using an established surgical surveillance system. Management and outcomes are described. Prognostic factors associated with death before surgery are explored.

Results

219 live-born infants with CDH were reported within the data collection period. There were 1.5 times more males vs females (n=133, 61%). Thirty-five infants (16%) died without an operation. This adverse outcome was associated with: female sex (aOR 3.96, 95%CI 1.66-9.47), prenatal diagnosis (aOR 4.99, 1.31-18.98) and the need for physiological support in the form of inotropes (aOR 9.96, 1.19-83.25) or pulmonary vasodilators (aOR 4.09, 1.53-10.93).

Significant variation in practice existed among centres and some therapies potentially detrimental to infant outcomes were used, including pulmonary surfactant in 45 antenatally diagnosed infants (34%). ECMO utilisation was very low compared to published international studies (n=9/219, 4%). Post-operative 30 day survival was 98% for 182 CDH infants that were adequately physiologically stabilised and underwent surgery.

Conclusion

This is the first British Isles population-based study reporting outcome metrics for infants born with CDH. 16% of babies did not survive to undergo surgery. Factors associated with poor outcome included female sex and prenatal diagnosis. Early post-operative survival in those who underwent surgical repair was excellent.

Introduction

'Congenital diaphragmatic hernia' (CDH) describes a spectrum of abnormalities ranging from small muscular defects to major aberrations in thoracic development affecting the lung and pulmonary vasculature. Recent decades have seen major advances in fetal medical and neonatal care, many of which have had an impact on outcomes for these infants [1]. Researchers and clinicians continue to strive to improve outcomes in infants born with CDH as survival of live-born infants has remained at 75-85% for the last two decades [2-4].

A strong evidence-base for most of the management practices utilised in CDH is conspicuously lacking [5, 6], although where evidence of benefit or harm exists, it has been used (in part) to inform European management guidelines [7]. We describe management practices at the time of data collection for infants born in the UK and Ireland. Variation in outcomes among centres and departure from evidence-based therapy(s) are reported. Prognostic factors linked to death before surgery are also explored.

Methods

This study received ethics committee approval from the London Research Ethics Committee: Ref 09/H0718/10.

Case identification

A prospective population cohort study was undertaken, collecting data from all 28 specialist paediatric surgical centres in the UK and Ireland over an 18-month period from April 2009 – September 2010. The surveillance methodology, using the British Association of Paediatric Surgeons Congenital Anomaly Surveillance System (BAPS-CASS) has been previously described [8]. In brief, designated paediatric surgeons at UK and Ireland surgical centre(s) are sent a monthly reporting card throughout the duration of the study, they then return the card with the number of cases seen in the preceding month or respond that they have not seen any cases.

Case definition

Infants eligible for study inclusion were those who presented to specialist paediatric surgical centres within the data collection period meeting the following case definition: any live-born infant with a congenital diaphragmatic hernia, defined as a developmental defect of the diaphragm present at birth allowing herniation of abdominal contents into the chest.

Data collection

After cases were reported to BAPS-CASS, data were collected from centres using a standardised data collection form and then double entered into a customised database. Duplicate cases were identified and removed. Missing data were sought from reporting centres and clinicians by email / telephone contact.

Statistical analyses

Statistical analyses were undertaken using *Stata 13*. Median and IQR values are presented for continuous data and differences analysed using Mann-Whitney tests. Chi² or Fisher's exact tests were used to assess differences in proportions between groups. Univariable and multivariable logistic regression analyses were performed to identify factors associated with death before surgery. Potential risk-factors were determined *a priori* from the literature. These included being small for gestational age (SGA), defined as being less than the 10th percentile for birthweight for gestational age using British normative data from the LMS growth study [9].

Risk factors with a significant odds ratio (OR) ($p < 0.10$) were included in a multivariable model in a step-wise forward method in order of their statistical significance. Covariates that improved the fit of the model on likelihood ratio testing were retained. Factors with a p value < 0.05 within the final model were considered statistically significantly associated with death before surgery.

Results

Two hundred and nineteen live-born infants with CDH were identified. During the eighteen-month surveillance period there were 1.3 million live births in the UK and Ireland giving an estimated live-birth prevalence of 1.7 per 10,000 (95% CI 1.5-1.9), or 1 in 5,880. The number of infants reported by individual centres ranged from 1-18 (IQR 4-12). Sixty-one percent of infants were male. Demographic information and characteristics of those presenting antenatally and postnatally are shown in Table 1.

Table 1. Demographics and antenatal management of infants with CDH in the cohort

	All n (%)	Antenatal Diagnosis n (%)	Postnatal Diagnosis n (%)	p value
Number in Cohort	219	134 (61)	85 (39)	
Male sex	133 (61)	84 (63)	49 (58)	0.48
Female sex	86 (39)	50 (37)	36 (42)	
Mothers age (median) N=210	29 (24-32)	28 (23.5-32)	29.5 (25-33)	0.32
White ethnicity N=217	187 (86)	111 (83)	76 (90)	0.16
Multiple pregnancy	11 (5)	6 (4)	5 (6)	0.75
Gestational age at birth (median)	39 (37-39)	38 (35-39)	39 (38-40)	<0.001
Birthweight (g) N=215	3010 (2609-3390)	2940 (2400-3235)	3270 (2850-3540)	<0.05
Gestational age at diagnosis (median, weeks) N= 118		20 (20-23)		
Polyhydramnios (%) N = 205	39 (19)	36 (29)	3 (4)	<0.001
Features suggesting AN dx N =134 Stomach in chest Liver in chest Mediastinal displacement Other feature		111 (83) 34 (25) 20 (15) 9 (7)		
Family history of CDH	1/218			
AN surgical counselling		98/126 (78)		
Mode of delivery Vaginal delivery Pre-labour C-Section In labour C-Section	149 (68) 35 (16) 36 (16)	86 (64) 24 (18) 24 (18)	62 (73) 11 (13) 12 (14)	0.19 0.35 0.58
Other anomalies N=217	62 (28)	38 (28)	24 (29)	1.00
Side of hernia Left Right Bilateral Central	178 (81) 37 (17) 1 3 (1)			

Continuous data presented as Median, IQR. Categorical data presented as n (%), calculated for those with complete data-
N=219 unless otherwise specified.

Antenatal findings and management

One hundred and thirty-four infants had CDH detected antenatally (61%). There was no statistical difference between the proportion of males (48/133, 63%) and females (50/86, 58%) whose CDH was detected antenatally ($p=0.467$). Where diagnosis of CDH was established antenatally, 78% of parents received prenatal counselling involving paediatric surgeons.

Postnatal management

Table 2 summarises postnatal management of the study cohort. Thirty-three antenatally diagnosed newborns (25%) were transferred to another hospital after delivery compared with 64 babies diagnosed postnatally (76%).

Table 2. Postnatal medical management in infants born with CDH

		All n (%)	Antenatal Diagnosis n (%)	Postnatal Diagnosis n (%)
Postnatal transfer	N=218	97 (44)	33 (25)	64 (76)
Cardiac echo performed	N=219	186 (85)	116 (87)	70 (82)
Surfactant given	N=216	53 (25)	45 (34)	8 (10)
28-32 wks gestation		10/16 (63)		
33-36 wks gestation		14/33 (42)		
>= 37 wks gestation		29/167 (17)		
Ventilation	N=219	198 (90)	134/134 (100)	64/85 (75)
Mode of invasive ventilation[§]				
Conventional		193 (97)	129 (96)	64 (100)
HFOV		87 (44)	74 (55)	13 (20)
ECMO		9 (5)	6 (4)	3 (5)
Liquid		1 (1)	0 (0)	1 (2)
Received inotropes	N=219	134 (61)	103 (77)	31 (36)
Pulmonary vasodilators after birth	N=218	78 (36)	64 (48)	14 (17)
Nitric oxide		75 (96)	61 (95)	14 (100)
Sildenafil		3 (4)	3 (5)	0 (0)
Other Agent		8 (10)	7 (11)	1 (7)

[§]Some infants had more than one mode, All data are n (%), N indicates infants with complete data
HFOV – High Frequency Oscillatory Ventilation, ECMO – extra-corporeal membrane oxygenation

Fifty-three (25%) of all infants were administered surfactant after delivery, 29 of these were born at term (17% of infants born at term). Forty-five antenatally diagnosed infants (34%) received surfactant; 24 of these were born at term, (26% of infants born at term following antenatal diagnosis). Seventy-eight babies received pulmonary vasodilator therapy(s) for pulmonary hypertension after birth (36%); 75 of these (96%) had inhaled nitric oxide.

1
2
3 All 134 antenatally diagnosed CDH infants and 64/85 (75%) of those postnatally diagnosed were
4 ventilated. Some infants received more than one mode of ventilation: 193 (97%) underwent
5 conventional mechanical ventilation and 87 (44%) high frequency oscillation. ECMO use was very
6 low among the cohort (9 infants, 4% of the cohort).
7
8
9

10
11
12 Sixty-one percent of CDH newborns received inotropes (n=134) with a statistically significant
13 difference in inotrope use between those diagnosed antenatally and postnatally (77% and 36%,
14 p<0.001).
15
16
17
18
19

20 21 *Surgical Management*

22
23 One hundred and eighty-two infants underwent surgical repair of their diaphragmatic hernia (83%).
24
25 Thirty-five infants (16%) died before surgery. One infant was lost to follow-up before surgery. Details
26 of surgical management are summarised in Table 3. Sixty-five percent of infants had primary repair
27 of the diaphragmatic defect (n=118). Thirty-five percent (n=64) underwent repair with a patch, 50%
28 and 16% in antenatally and postnatally diagnosed infants respectively (p<0.001). There was no
29 statistical difference in the proportions of female and male newborns who underwent patch
30 diaphragm reconstruction (23/63, 37% vs 41/119, 34% p=0.782).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Surgical management of infants in the cohort

	All Infants	AN diagnosis	Postnatal diagnosis
Had surgery N=218	182 (83)	101 (76)	81 (95)
Operation type N=182			
Primary repair	118 (65) 18/115 (16) Absorbable 97/115 (84) Non-absorbable		
Patch repair	64/182(36) 22/63 (35) Biological 41/63 (65) Synthetic	51/101 (50) [‡]	13/81 (16) [‡]
Abdominal wall patch	11/179 (6)		
Double patch*	8/179 (4)		
Chest drain inserted	17 (9)		
Thoracoscopic repair	14 (8)	5/101 (5%)	9/81 (11%)
Other operation[‡]			
Fundoplication [‡]	3 (2)		
Correction of malrotation	21 (12)		
Appendicectomy alone	7/180 (4)		
Other	12/180 (7)		

*Patches on diaphragm and abdominal wall [‡] Other operation at time of CDH repair [‡] p<0.001

Early outcomes

Of the 182 infants that underwent surgical repair, four died within 30 days of surgery giving a 30 day post-operative survival rate of 98%. Two infants had a recurrence of their CDH within 30 days of surgery. Twelve infants developed chylothorax following surgery (7%).

1
2
3 *Factors associated with mortality before surgical correction of CDH*
4

5
6 The relationship between a number of factors and death without surgery were assessed with
7
8 univariable logistic regression (Table 4). In addition to those factors shown in Table 4, the
9
10 relationship between use of surfactant and death before surgery was assessed by univariable logistic
11
12 regression analysis. The unadjusted odds ratio for the use of surfactant in all infants was 3.35 (1.57-
13
14 7.14). In those born at <37 weeks gestation the OR was 0.80 (0.19-3.42) and for babies born at ≥37
15
16 weeks OR was 6.59 (2.60-16.71). As the impact of surfactant utilisation appeared so different in term
17
18 and preterm babies, this was not added to the multivariable model.
19

20
21 The use of pulmonary vasodilators after birth, inotrope use, pre and post-natal diagnosis, female sex
22
23 and gestational age at birth all met the criteria for inclusion in the multi-variable analysis and were
24
25 entered into the model in that order. The first four of these factors were retained within the model
26
27 after likelihood ratio testing and all were statistically significant in the final model. The results of the
28
29 multivariable analysis are summarised in Table 5.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4. Univariable logistic regression to assess factors associated with death before surgery

Variable	Had an Op	Died with no Op	p value	OR* (95% CI)
Female sex	63 (35%)	22 (63%)	0.002	3.20 (1.51-6.77)
Male Sex	119 (65%)	13 (37%)		
White Ethnicity	154 (85%)	31 (91%)	0.353	1.81 (0.52-6.35)
Multiple Pregnancy	10 (5%)	1 (3%)	0.522	0.51 (0.06-4.08)
Gestational Age at Birth per week GA	39 (37-39)	38 (36-39)	0.093	0.90 (0.80-1.02)
Birth-weight per 500g increase in BW	3025 (2650-3400)	2920 (2175-3230)	0.110	0.81 (0.62-1.05)
SGA	20/178 (11%)	7/35 (20%)	0.160	1.97 (0.76-5.11)
Pre/ post-natal diagnosis	101/182 (55%) AN	32/35 (91%) AN	0.001	8.55 (2.53-28.95)
Associated anomalies	39 (21%)	5 (14%)	0.340	0.61 (0.22-1.68)
Cardiac anomalies	19 (10%)	1 (3%)	0.187	0.25 (0.03-1.95)
Genetic anomalies	5 (3%)	1 (3%)	0.971	1.04 (0.12-9.19)
Liver in the chest if antenatally diagnosed	26 (26%)	8 (25%)	0.933	0.96 (0.38-2.40)
Side of Hernia				
Left	147 (82%)	30 (86%)	0.567 [†]	1.35 (0.49-3.73)
Right	33 (18%)	5 (14%)		
Inotropes Used	99 (54%)	34 (97%)	0.001	28.51 (3.82-212.71)
Vasodilators after birth	49 (27%)	28 (80%)	<0.001	10.78 (4.42-26.26)

Continuous data presented as Median, IQR. *unadjusted odds ratio. SGA- Small for gestational age

[†] Left vs right

Table 5. Multivariable logistic regression to assess factors associated with death before surgery

Variable	p value	Adjusted Odds Ratio (95% CI)
Vasodilators after birth	0.005	4.09 (1.53-10.93)
Inotropes used	0.034	9.96 (1.19-83.25)
Prenatal diagnosis	0.018	4.99 (1.31-18.98)
Female sex	0.002	3.96 (1.66-9.47)

Discussion

A population-based assessment of incidence, management and early post-operative outcomes of CDH has been undertaken for the first time in the UK and Ireland. Consistent with the findings of several recent studies, we observed that there were 1.5 times as many male live-born infants with CDH as female (61% v 39%) [10, 11].

Sixteen percent of infants died before surgery. Factors associated with poor outcome were identified. Two factors, the use of inotropes and vasodilators after birth are hallmarks of severe physiological instability. The prognostic significance of diagnosis before birth was also strikingly apparent within this cohort with antenatally diagnosed infants almost five times more likely to die before surgery than those detected postnatally, a reflection of the greater anatomical severity of CDH in antenatally diagnosed fetuses. Twenty-four percent of newborns with prenatal diagnosis died without having an operation, in comparison to 4% of CDH cases who had defects detected in the postnatal period. It is also noteworthy that a larger proportion of antenatally diagnosed CDH babies had inotropes administered before surgery (77% vs 36%, $p<0.001$) emphasising their greater likelihood of physiological instability. In addition, more underwent patch repair (50% vs 16 %, $p<0.001$).

We found that female infants were more likely to die without undergoing surgery than males (26% and 10% respectively). This association with gender was statistically significant even after adjusting for prenatal diagnosis and the two markers of physiological instability. A large study from the CDH study group likewise identified that female infants were more likely to die before hospital discharge [10]. It could be postulated that female sex is associated with more severe pulmonary hypoplasia and hence girls are less likely to be stable enough to undergo surgery. It is noteworthy though that females were just as likely to have CDH defects detected antenatally as males ($p=0.48$). Our study results showed no difference(s) in the number of females and males having patch repair ($p=0.782$), although the defect sizes of those who died before surgery remains unknown.

1
2
3 There is some emerging evidence that there may be sex-related differences in the genetics of
4 isolated CDH with females carrying more *de novo* coding variants, however the correlation between
5 genetic aetiology and CDH severity is as yet unclear [12]. The reasons for the higher proportion of
6 females dying before operative repair of CDH merits further investigation.
7
8
9

10
11
12 Whilst 16% of infants died without undergoing an operation, it is useful to report that only a small
13 number of early post-operative deaths were identified in the study cohort. This could be a product
14 of related phenomena: case selection of infants who are physiologically stable and appropriate
15 surgical candidates and excellent post-operative care in individual centres. It is also necessary to
16 assess outcomes beyond 30 days to provide meaningful data on longer-term post-operative survival.
17
18
19
20
21

22
23
24 The strength of this study is that it represents, for the first time a comprehensive population-based
25 assessment of early outcomes in CDH across individual surgical centres, with all paediatric surgery
26 centres in the UK and Ireland contributing data to the study. The live-birth prevalence of 1.7 per
27 10,000 is somewhat lower than that estimated during the year(s) 2009-2010 from geographic
28 regions covered by the British Association of Congenital Anomalies Register(s) (BINOCAR) (2.66
29 (95%CI 2.24-3.15))[13]; the exact reasons for this difference in ascertainment are unclear. While the
30 dataset reported here includes only those cases reported to paediatric surgeons, established
31 ascertainment methodology, meticulous chasing of incomplete data and querying of inconsistent
32 responses means that we are confident that the dataset presents a true picture of surgically treated
33 CDH cases for the period in question. However, as this study collected data from surgical centres
34 only, it is possible that some infants who were born alive, died outside of these centres and surgeons
35 were not informed of this. The number of these infants is likely to be very small as antenatally
36 diagnosed CDH deliveries are planned routinely to take place in surgical centres and the rate of non-
37 survival in postnatally diagnosed infants is low. Cross-validation with the congenital anomalies
38 registers existent at the time of the study may have helped to identify such cases in the areas
39 covered by these registers.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The relatively small number of infants presenting with CDH at each specialist centre is noteworthy,
4
5 (median 5 newborns per centre annually) and precluded any meaningful outcome comparison
6
7 between units. The influence on outcome of birth in a low-volume centre has been widely debated,
8
9 with studies from CAPSNET and Scandinavia suggesting improved survival in hospitals managing
10
11 more than five or six CDH cases a year [14, 15]. Controversially however a recent large study from
12
13 the USA was not able to demonstrate any clear relationship between CDH mortality and
14
15 management in high versus low volume centres, (OR 1.03, 95%CI 0.86-1.23) [3]. The small number of
16
17 cases managed in individual surgical centres across the UK and Ireland does however bring into
18
19 sharp focus a crucial need for collaborative research platforms through organisations such as BAPS-
20
21 CASS, CAPSNET, CDH study group, the National Congenital Anomaly and Rare Disease Registration
22
23 Service (NCARDRS) and the CDH European consortium to collectively study, analyse and report large
24
25 data sets to inform 'best practice' for rare diseases.
26
27
28
29

30 Variation in practice in pre and postnatal CDH care across individual centres in the UK and Ireland
31
32 was readily apparent from this study. It is notable that 22% of parents that had an antenatal
33
34 diagnosis of CDH did not receive counselling from a paediatric surgeon before the birth of their baby.
35
36 This is an area where improvements must be made to facilitate multidisciplinary antenatal
37
38 counselling and reflects recommendations issued by the MBBRACE UK 2014 Perinatal Confidential
39
40 Enquiry into CDH [16]. Counselling by surgeons alongside obstetricians and neonatologists affords
41
42 the opportunity for knowledge exchange and information sharing with regard to the prognosis for
43
44 the fetus including the site and mode of delivery, newborn management and long-term outcome(s).
45
46 There is strong evidence that counselling by paediatric surgeons before birth reduces levels of
47
48 parental anxiety and parents value this interaction [17-20].
49
50
51
52
53
54
55
56
57
58
59
60

Current practice regarding the use of exogenous surfactant therapy as part of early postnatal CDH management is inconsistent. In this study, approximately one-third of all newborns with antenatally detected CDH received surfactant. There was some evidence that this may increase the risk of death before surgery in term infants (OR 6.59, 95% CI 2.60-16.71). It is likely though, that term babies that received surfactant may have been more unstable leading neonatologists to use it as a perceived 'salvage' therapy. Although the quality of the evidence remains poor, studies have emerged suggesting the use of surfactant in infants with CDH may adversely affect survival and be linked with the development of chronic lung disease [21, 22]. Current European guidelines advise against the use of this costly and potentially harmful intervention in infants born with CDH either at or before term [7].

The very limited use of ECMO in infants with CDH across the UK and Ireland in this study cohort is noteworthy. Five centres currently provide this facility and infants are transferred to these units for ECMO where appropriate. Only 4% of the entire CDH cohort received ECMO. This is in marked contrast to contemporary study series from ECMO centres across the USA where ECMO is deployed for over half of all CDH infants [23]. The CDH international study group, has also reported a wide variation in usage of ECMO, noting that on average 30% of infants received this therapy particularly in high volume centres[1]. The low utilisation of ECMO in the UK and Ireland reported here probably reflects a more judicious use of this high-cost health care intervention with little evidence of clinical efficacy [5, 7].

Conclusions

This study shows variation in the management of CDH in the UK and Ireland before, during and after birth. Mortality remains high for this rare condition, with some 16% of all live-born CDH infants not surviving to undergo surgical repair. Published outcomes should be clearly stratified by criteria of disease severity including antenatal diagnosis and size of diaphragm defect. The small number of CDH babies managed in individual surgical centres further highlights the need for neonatal networks and collaborative multidisciplinary research to generate robust outcome data and facilitate interventional studies to improve outcomes.

Funding

This project was funded by Action Medical Research

What is already known about this subject

- Congenital diaphragmatic hernia is a rare disease with an incidence 1 in 3000 births
- Newborns with prenatally diagnosed congenital diaphragmatic hernia have more severe birth defects and worse survival outcomes

What this study adds

- Evidence of clinical variation in pre and postnatal management of CDH across centres in the UK and Ireland including deviation from 'best practice' strategies.
- Evidence that live-born females with CDH are more likely to die before surgery than male infants

Acknowledgements

We acknowledge the support, dedication and hard work of all those who contributed to this study. Sean Marven, Elizabeth Draper, Paul Johnson, Peter Brocklehurst, David Howe and Judith Rankin were involved in the original set-up and design of the study.

Contributorship Statement

Professors Losty, Knight and Kurinczuk designed and coordinated the study along with the BAPS-CASS collaboration. Anna-May Long and Kathryn Bunch analysed the data and Anna-May Long wrote the manuscript which was reviewed and edited by all other authors.

References

1. Lally, K.P. Congenital diaphragmatic hernia - the past 25 (or so) years. *J Pediatr Surg*. 2016;51(5):695-8.
2. Stege, G., A. Fenton, and B. Jaffray, Nihilism in the 1990s: the true mortality of congenital diaphragmatic hernia. *Pediatrics*. 2003;112(3):532-5.
3. Kane, J.M., Harbert, J. Hohmann, S. et al., Case Volume and Outcomes of Congenital Diaphragmatic Hernia Surgery in Academic Medical Centers. *Am J Perinatol*. 2015;32(9):845-52.
4. Beaumier, C.K., Beres, A.L. Puligandla, P.S. et al., Clinical characteristics and outcomes of patients with right congenital diaphragmatic hernia: A population-based study. *J Pediatr Surg*. 2015;50(5):731-3.
5. Losty, P.D., Congenital diaphragmatic hernia: where and what is the evidence? *Semin Pediatr Surg*. 2014;23(5):278-82.
6. Puligandla, P.S., Grabowski, J., Austin, M. et al., Management of congenital diaphragmatic hernia: A systematic review from the APSA outcomes and evidence based practice committee. *J Pediatr Surg*. 2015;50(11):1958-70.
7. Snoek, K.G., Peters, N.C.J. van Rosmalen, J., et al., Standardized Postnatal Management of Infants with Congenital Diaphragmatic Hernia in Europe: The CDH EURO Consortium Consensus - 2015 Update. *Neonatology*. 2016;110(1):66-74.
8. Owen, A., Marven S. Johnson, P., et al., Gastroschisis: a national cohort study to describe contemporary surgical strategies and outcomes. *J Pediatr Surg*. 2010;45(9):1808-16.
9. Cole, T.J., The LMS method for constructing normalized growth standards. *Eur J Clin Nutr*. 1990;44(1):45-60.
10. Brindle, M.E., Cook, E.F., Tibboel, D. et al., A clinical prediction rule for the severity of congenital diaphragmatic hernias in newborns. *Pediatrics*. 2014;134(2):e413-9.
11. Brindle, M.E., M. Brar, and E.D. Skarsgard, Patch repair is an independent predictor of morbidity and mortality in congenital diaphragmatic hernia. *Pediatr Surg Int*. 2011;27(9):969-74.

12. Qi H., Yu, L., Zhou, X., et al Genetic analysis of de novo variants reveals sex differences in complex and isolated congenital diaphragmatic hernia and indicates MYRF as a candidate gene. 2017. [cited November 2017]. Available from: <https://www.biorxiv.org/content/biorxiv/early/2017/11/12/206037.full.pdf>
13. EUROCAT. 2009 [cited 2016 September]; Available from: <http://www.eurocat-network.eu/accessprevalencedata/prevalencetables>.
14. Javid, P.J., Jaksic, T., Skarsgard, E.D., et al., Survival rate in congenital diaphragmatic hernia: the experience of the Canadian Neonatal Network. *J Pediatr Surg*. 2004;39(5):657-60.
15. Skari, H., Bjornland K., Haugen, G., et al., Congenital diaphragmatic hernia: a survey of practice in Scandinavia. *Pediatr Surg Int*. 2004;20(5):309-13.
16. Field, D., Hyman-Taylor, P., Bacon, C. and Draper, E.S., Perinatal Confidential Enquiry - Congenital Diaphragmatic Hernia, in Maternal, Newborn and Infant Clinical Outcome Review Programme, (MBRRACE-UK), Editor. 2014, University of Leicester: Department of Health Sciences.
17. Patel, R.R. and T. Overton, Suspected fetal anomalies. *Obstetrics, Gynaecology and Reproductive Medicine*, 2008. 18(5): p. 134-138.
18. Aite, L., Trucchi, A. Nahom, A. et al., Antenatal diagnosis of surgically correctable anomalies: effects of repeated consultations on parental anxiety. *J Perinatol*, 2003. 23(8): p. 652-4.
19. Kemp, J., M. Davenport, and A. Pernet, Antenatally diagnosed surgical anomalies: the psychological effect of parental antenatal counseling. *J Pediatr Surg*, 1998. 33(9): p. 1376-9.
20. Aite, L., Trucchi, A. Nahom, A. et al., Antenatal diagnosis of diaphragmatic hernia: parents' emotional and cognitive reactions. *J Pediatr Surg*, 2004. 39(2): p. 174-8; discussion 174-8.
21. Van Meurs, K., Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia? *J Pediatr*, 2004. 145(3): p. 312-6.
22. Lally, K.P., Lally, P.A. Langham, M.R. et al., Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia. *J Pediatr Surg*, 2004. 39(6): p. 829-33.
23. Coughlin, M.A., Werner, N.L., Gakarski, R., et al., Prenatally diagnosed severe CDH: mortality and morbidity remain high. *J Pediatr Surg*, 2016. 51(7): p. 1091-5.